Kidney Cancer Triple-Drug Trial Fails Primary Goals
The study found no added survival benefit for patients using a new three-drug regimen compared to standard treatment.
Updated on Oct. 25, 2026 in Cancer
Live Poll
Do you believe adding more drugs to an existing treatment plan usually improves patient outcomes?
The LITESPARK-012 trial of 1,688 patients failed to meet primary survival goals for advanced clear cell renal cell carcinoma. The study tested adding experimental drugs to the standard Keytruda and Lenvima treatment, which remains an established first-line option.
Why it matters
This result prevents a change in the current standard of care for patients with advanced kidney cancer. The trial found that adding extra medications did not improve survival outcomes while significantly increasing the rates of treatment discontinuation.
This Phase 3 trial randomized 1,688 patients to test triple-drug regimens against a two-drug standard, finding no improvement in overall or progression-free survival. Investigators observed significantly higher withdrawal rates in the experimental arms compared to the control group.
The players
Merck
A pharmaceutical company that produces oncology therapeutics including Keytruda.
Eisai
A pharmaceutical company that collaborates on cancer treatments including Lenvima.
The details
The trial investigated whether adding belzutifan or MK-1308A to Keytruda and Lenvima could better target tumors. Many clear cell tumors possess VHL gene mutations that activate HIF-2 alpha, a protein complex that fuels tumor growth. However, participants receiving these combinations withdrew from treatment at rates exceeding 51%, compared to 36.2% for the standard two-drug regimen.
Timeline
August 2021: FDA approved Keytruda plus Lenvima for kidney cancer.
December 2023: FDA approved belzutifan for previously treated kidney cancer.
April 2026: Merck and Eisai announced the negative LITESPARK-012 trial results.
October 25, 2026: Full trial results were presented at the ESMO Congress in Madrid.
Health Landscape
The LITESPARK-012 trial provides a critical negative data point in the ongoing effort to enhance first-line immunotherapy for renal cell carcinoma. This outcome reinforces the current standard of care while highlighting the challenges of increasing drug intensity for advanced kidney cancer patients.
This study confirms that the established Keytruda and Lenvima combination remains a standard first-line choice for eligible patients. Anyone managing advanced kidney cancer should discuss their current treatment plan and any concerns about side effects or withdrawal with their oncologist.
The takeaway
The addition of investigational agents to standard kidney cancer therapy did not improve survival and increased treatment discontinuation rates. Patients should rely on established protocols and maintain open communication with their care team regarding side effects.
Further reading
For more on evolving research, visit our Cancer section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you believe adding more drugs to an existing treatment plan usually improves patient outcomes?
